Home › Funds › Bellevue Group AG › IMCR
Bellevue Group AG position in IMCR
IMMUNOCORE HLDGS PLC · Health Care
Bellevue Group AG reported holding 2,264,321 shares of IMCR (IMMUNOCORE HLDGS PLC) in its Q3 2026 13F filing — a position valued at US$68.6M, representing 1.42% of its reported portfolio and ranking #19 among its reported holdings. Bellevue Group AG has disclosed IMCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's IMCR position evolved
Bellevue Group AG first disclosed a stake in IMCR in Q3 2023 at 19,850 shares (US$1.0M). The position peaked in Q3 2025 at 2,796,803 shares, worth US$101.6M. Across 13 filings, Bellevue Group AG increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 2,264,321 shares valued at US$68.6M — a reduction of -523,924 shares quarter over quarter.. Notable position changes include a 4817% increase in Q4 2023 (shares fell 5% over the following quarter), a 100% increase in Q2 2025 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 19.85K | $1.03M | New |
| Q4 2023 | 976.05K | $66.68M | Add |
| Q1 2024 | 972.25K | $63.20M | Hold |
| Q2 2024 | 1.15M | $39.13M | Add |
| Q3 2024 | 1.21M | $37.53M | Add |
| Q4 2024 | 1.21M | $35.56M | Hold |
| Q1 2025 | 1.22M | $36.25M | Add |
| Q2 2025 | 2.44M | $76.62M | Add |
| Q3 2025 | 2.80M | $101.61M | Add |
| Q4 2025 | 2.80M | $97.08M | Hold |
| Q1 2026 | 2.80M | $84.32M | Hold |
| Q2 2026 | 2.79M | $88.53M | Hold |
| Q3 2026 | 2.26M | $68.59M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMCR and 13F data
IMCR (IMMUNOCORE HLDGS PLC) is a Health Care company. 27 other funds we track also report a position in IMCR — the largest reported positions include RTW INVESTMENTS, LP (US$147.5M), TANG CAPITAL MANAGEMENT LLC (US$87.4M), Caligan Partners LP (US$50.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMCR
- RTW INVESTMENTS, LP 4.87M sh · $147.51M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 2.88M sh · $87.36M · Q3 2026
- Caligan Partners LP 1.67M sh · $50.65M · Q3 2026
- Kynam Capital Management, LP 1.38M sh · $41.65M · Q3 2026
- BVF INC/IL 1.23M sh · $37.28M · Q3 2026
- MPM BioImpact LLC 1.20M sh · $36.45M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.14M sh · $34.41M · Q3 2026
- Trails Edge Capital Partners, LP 1.06M sh · $32.21M · Q3 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 928.00K sh · $28.11M · Q3 2026
- BRAIDWELL LP 906.12K sh · $27.45M · Q3 2026
- Vestal Point Capital, LP 850.00K sh · $25.75M · Q3 2026
- Frazier Life Sciences Management, L.P. 829.75K sh · $25.13M · Q3 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held IMCR?
Bellevue Group AG has disclosed IMCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in IMCR?
As of Q3 2026, Bellevue Group AG holds 2.26M shares of IMCR (IMMUNOCORE HLDGS PLC), valued at $68.59M, representing 1.42% of its reported portfolio and ranking #19.
Has Bellevue Group AG been buying or selling IMCR?
In the latest 13F filing (Q3 2026), Bellevue Group AG reduced its position in IMCR. The position peaked in Q3 2025 at 2.80M shares.
Which other funds hold IMCR?
Other major institutional holders of IMCR include RTW INVESTMENTS, LP, TANG CAPITAL MANAGEMENT LLC, Caligan Partners LP, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.